

BRAWN BIOTECH LIMITED

(Formerly known as Brawn Pharmaceuticals Limited)

Regd. Office : C-64, Lajpat Nagar-I, New Delhi-110024

CIN: L74899DL1985PLC022468

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2014

(Rs. in Lacs)

PARTICULARS	3 months ended 30/06/2014	Preceding 3 months ended 31/03/2014	Corresponding 3 months ended 30/06/2013 in the previous year	Previous year ended 31/03/2014
	Unaudited	Unaudited	Unaudited	Audited
PART-I				
1. Income from Operations				
a. Net Sales/ Income from operations (Net of Excise Duty)	747.15	945.09	790.27	3,670.43
b. Other Operating Income	12.02	30.01	11.67	106.81
Total Income from operations (Net)	759.18	975.10	801.94	3,777.24
2. Expenses				
a. Cost of Materials Consumed				
b. Purchase of Stock in Trade	- 620.13	579.93	494.76	2,830.54
c. Change in Inventories of Finished Goods, work-in-Progress and Stock-in-Trade	40.58	(32.00)	45.97	(11.23)
d. Employee Benefits Expenses	34.90	59.76	88.99	283.35
e. Depreciation and amortisation expenses	0.76	0.47	0.37	1.47
f. Other Expenditure	52.88	347.62	88.60	629.77
Total Expenses	749.25	955.77	718.69	3,733.90
3. Profit/ (loss) from Operations before Other Income, Finance Cost and Exceptional Items (1-2)	9.92	19.33	83.25	43.35
4. Other Income	0.29	2.45	-	71.24
5. Profit/ (Loss) from ordinary activities before Finance Cost and Exceptional Items (3+4)	10.22	21.79	83.25	114.59
6. Finance Cost	0.29	11.12	0.19	14.20
7. Profit/ (Loss) from ordinary activities after Finance Cost but before Exceptional Items (5-6)	9.93	10.67	83.06	100.39
8. Exceptional Items		36.23	-	77.63
9. Profit/(+)/Loss(-) from Ordinary Activities before tax (7-8)	9.93	(25.57)	83.06	22.76
10. Tax Expenses	3.07	(4.39)	20.22	10.55
11. Net Profit (+)/ Loss (-) from Ordinary Activities after tax (9-10)	6.86	(21.18)	62.84	12.21
12. Extraordinary Items (net of tax expenses)				
13. Net Profit(+)/ Loss(-) for the period (11-12)	6.86	(21.18)	62.84	12.21
14. Paid-up equity share capital (Face Value of the Share is Rs.10/- each)	300.03	300.03	300.03	300.03
15. Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	172.56	165.70	181.07	165.7
16I. Earnings Per Share (before extraordinary items) (not annualised) in Rs.				
(a) Basic	0.23	(0.71)	2.09	0.39
(b) Diluted	0.23	(0.71)	2.09	0.39
16II. Earnings Per Share (after extraordinary items) (not annualised) in Rs.				
(a) Basic	0.23	(0.71)	2.09	0.39
(b) Diluted	0.23	(0.71)	2.09	0.39

PART-II INFORMATION FOR THE QUARTER ENDED 30th JUNE, 2014

PARTICULARS	3 months ended 30/06/2014	Preceding 3 months ended 31/03/2014	Corresponding 3 months ended 30/06/2013 in the previous year	Previous year ended 31/03/2014
A PARTICULARS OF SHAREHOLDING				
1. Public Shareholding				
- Number of Shares	15,64,224	15,64,224	15,64,324	15,64,224
- Percentage of shareholding	52.14	52.14	52.14	52.14
2. Promoters and promoter				
a. Pledged/Encumbered	Nil	Nil	Nil	Nil
- Number of Shares	Nil	Nil	Nil	Nil
- Percentage of shareholding (as a % of the total shareholding of promoter and promoter group)	Nil	Nil	Nil	Nil
- Percentage of shareholding (as a % of the total Share Capital of the Company)	Nil	Nil	Nil	Nil
b. Non-encumbered				
- Number of Shares	14,36,076	14,36,076	1,435,976	14,36,076
- Percentage of shareholding (as a % of the total shareholding of promoter and promoter group)	100.00	100.00	100.00	100.00
- Percentage of shareholding (as a % of the total Share Capital of the Company)	47.86	47.86	47.86	47.86

Particulars 3 Months ended 30th June, 2014

B INVESTOR COMPLAINTS				
Pending at the beginning of the Quarter				NIL
Received during the Quarter				NIL
Disposed of during the Quarter				NIL
Remaining unresolved at the end of the Quarter				NIL

Notes: 1. The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors in their Meeting held on 13.08.2014. 2. The Statutory Auditors have carried out a Limited Review of the Financial Results for the Quarter ended 30th June, 2014. 3. The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Accounting Standard-17 dealing with Segment Reporting. Figures of the previous periods have been re-grouped, wherever necessary, to conform to the current periods classification.

For and on behalf of the Board
For Brawn Biotech Limited

Place: New Delhi
Date : 13.08.2014

Sd/
Director